Effective March 1, 2010, the Siegfried Group (SIX: SFZN) will introduce a functional organization to replace its current two-division structure.

Siegfried Generics Malta Ltd. successfully passed inspection by the MAM (Maltese regulatory authority).  The inspection certified the new microbiological testing lab and also extended our manufacturing license to include activities such as the production of clinical testing samples.  ...

For the first nine months of the 2009 financial year, the Siegfried Group (SIX: SFZN) reported sales of 201.5 million Swiss francs, or 5.6% less than in the comparable period the previous year. Adjusted for a one-time royalty payment for a biogeneric drug in the 2008 financial year, the Siegfried ...

The Zofingen-based Siegfried Group (SWX SFZN) announces the departure of Heinrich Hoppmann, the head of its Generics Division, effective October 31, 2008. Hoppmann has accepted a new position and leaves the company by reciprocal agreement.

Clinical trial manufacturing for inhalation products